Tenoxicam 20 mg

TENOXICAM 20 is the trade name of Tenoxicam, a new thienothiazine derivative of the oxicam class with a non-steroidal anti-inflammatory and an analgesic action.

Each TENOXICAM 20 Capsule contains 20 mg of Tenoxicam.

 

CHEMISTRY

Tenoxicam is: 4-hydroxy-2-methyl-N-2-pyridinyl-2H-thieno[2,3-e]-1,2-thiazine-3-carboxamide 1,1-dioxide.

 

CLINICAL PHARMACOLOGY

TENOXICAM 20 inhibits prostaglandin synthesis by inhibiting cyclo-oxygenase, which catalyses the formation of cyclic endoperoxidase from arachidonic acid.  The resultant decrease in prostaglandin synthesis and the scavenging of active oxygen radicals and the inhibition of generation of such species at inflammation site contribute to its main therapeutic effects. TENOXICAM 20 possesses a long duration of action which enables it to be administered once daily.  TENOXICAM 20 is highly absorbed when administered orally or rectally.  The oral route yields higher absorption.

 

INDICATIONS

Symptomatic treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis.

For the relief of pain of acute gouty arthritis and various nonarticular inflammatory processes.

Category:
DOSAGE
PREGNANCY AND LACTATION
INTERFERENCE
DRUG INTERACTIONS
CONTRAINDICATIONS
HOW SUPPLIED

DOSAGE

Usual adults dose 20 mg once daily the dose should not exceed 20 mg as this does not significantly improve efficacy but does increase the frequency and intensity of adverse reactions. For acute attacks of gouty arthritis the recommended dose is 40 mg once daily for two days followed by 20 mg once daily for a further 5 days. Usual pediatric dose No dose recommendations have so far been established for patients under 18 years of age. Note: TENOXICAM 20 Capsule should be swallowed with a full glass of water after meals, and at the same time each day.

PREGNANCY AND LACTATION

USE IN PREGNANCY AND LACTATION No teratogenic effects were seen in animal studies. In humans, however, the safety during pregnancy or lactation has not yet been established.

INTERFERENCE

INTERFERENCE WITH CLINICAL AND LABORATORY TESTS Tenoxicam has not been shown to produce any changes or abnormalities in laboratory values.

DRUG INTERACTIONS

Concomitant administration of more than one NSAIDs may increase the risk of gastrointestinal ulceration and bleeding. Concomitant administration with oral anticoagulants, systemically administered heparin, ticlopidine and thrombolytic agents: increased risk of hemorrhage. Diuretics treatment with NSAIDs is associated with potential acute renal insufficiency in patients who are dehydrated. Antihypertensive treatment (diuretics, vasodilatores,, beta-blockers, ACE-inhibitores) with NSAIDs, a reduced effect of the antihypertensive drugs has been reported. NSAIDs increase lithium plasma levels. It is recommended to monitor plasma lithium levels, when initiating treatment. As with other NSAIDs, tenoxicam may increase the hematological toxicity of Methotrexate. Cholestyramine increased the apparent clearance of tenoxicam by 105%. Tenoxicam may decrease the effect of intra-uterine device.

CONTRAINDICATIONS

Because of potential cross-sensitivity to other NSAIDs, it is contraindicated in patients in whom aspirin, iodides, or other NSAIDs have induced symptoms of asthma, rhinitis, urticaria, nasal polyps, angioedema or bronchospams.

HOW SUPPLIED

Carton Box (12 capsules / 2 PVC-Al blisters) + pamphlet Carton Box (8 capsules / PVC-Al blister) + pamphlet Carton Box (16 capsules / 2 PVC-Al blisters) + pamphlet Carton Box (10 capsules / PVC-Al blister) + pamphlet Carton Box (20 capsules / 2 PVC-Al blisters) + pamphlet Carton Box (30 capsules / 3 PVC-Al blisters) + pamphlet Hospital packs of different presentations. Store according to conditions specified on the package.

Related products